A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice.

Prior treatment

• Currently participating in an anifrolumab early access/compassionate use program or an interventional clinical trial with an investigational product.
• Any previous exposure to anifrolumab (including as part of a clinical trial or early access programme).
• Documented diagnosis of severe or rapidly progressive Class III or IV glomerulonephritis requiring induction therapy (mycophenolate mofetil \[MMF\]/cyclophosphamide \[CYC\] + high dose steroids), isolated Class V lupus nephritis (in absence of other SLE manifestations, ie. skin/joint involvement), or active severe or unstable neuropsychiatric lupus.

Other illness

• Any other condition which the investigator deems to limit a patient's ability to understand the informed consent.

• Fulfilled the 2019 EULAR (European League Against Rheumatism)/ACR (American College of Rheumatology) criteria for SLE at the time of study entry.
• Prescribed anifrolumab for their SLE treatment for the first time, according to approved country-specific label.
• The Physician's decision to prescribe anifrolumab must occur prior to any study-related discussion.
• In countries where prescription reimbursements are authorised on a case-by-case basis, authorisation (ie, patient access to treatment) will be required for study entry.